Indo Borax and Chemicals has launched a mandatory open offer to acquire a 25.79% stake in Kronox Lab Sciences following its recent takeover. Shareholders are invited to tender their shares at Rs 157.27 each between November 6 and November 20, 2026. This move follows Indo Borax’s acquisition of a 64.26% controlling stake in the company.
Indo Borax Launches Open Offer for Kronox Lab Sciences
Offer Price: Rs 157.27 per share
Total Consideration: Rs 150.50 crore
Reader Takeaway: Investors can exit via the open offer at a fixed price, but must weigh tax implications carefully.
What just happened
Indo Borax and Chemicals Limited has officially launched a mandatory open offer for Kronox Lab Sciences Ltd. This follows the acquirer's purchase of a 64.26% stake in Kronox on September 29, 2026. The offer covers 95,70,000 shares, representing 25.79% of the target company's voting share capital. The tendering window for shareholders will remain open from November 6, 2026, to November 20, 2026.
Why this matters
Under SEBI regulations, an acquirer gaining majority control of a listed entity must provide public shareholders an opportunity to exit or participate in the change of ownership. By offering Rs 157.27 per share, Indo Borax is fulfilling its regulatory obligation. Following the acquisition, the board of Kronox Lab Sciences has been fully reconstituted with representatives from the acquirer.
What changes now
Indo Borax has officially assumed the role of promoter for Kronox Lab Sciences. The company intends to integrate the business into its long-term strategy of portfolio diversification. Shareholders choosing to participate must route their trades through their respective brokers via the exchange acquisition window. Payment for accepted shares is expected within 10 working days after the offer closes.
Risks to watch
Shareholders should monitor the public shareholding levels of Kronox Lab Sciences, which must remain at or above 25% to comply with regulatory standards. While the acquirer has committed to maintaining these levels, any deviation could prompt future regulatory requirements. Additionally, shareholders should factor in brokerage costs and individual tax liabilities, as the net realization from the sale will vary based on their specific holding period and tax residency.
What to track next
The final outcome of the offer will depend on how many shares are tendered by public shareholders. Investors should ensure their DP accounts are updated and contact their brokers to understand the specific tender process during the November 6-20 window.